Intravenous anesthetic combination (hypnotic + opioid)
This page covers all Intravenous anesthetic combination (hypnotic + opioid) drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting GABA-A receptor (propofol); mu opioid receptor (alfentanil), GABA-A receptor, GABA-A receptor (propofol); voltage-gated sodium channels (lidocaine).
Targets
GABA-A receptor (propofol); mu opioid receptor (alfentanil) · GABA-A receptor · GABA-A receptor (propofol); voltage-gated sodium channels (lidocaine) · GABA-A receptor (propofol); mu-opioid receptor (alfentanil) · NMDA receptor (ketamine); GABA-A receptor (propofol) · GABA-A receptor (propofol); mu-opioid receptor (remifentanil)
Marketed (5)
- Propofol and Alfentanil · North District Hospital · Anesthesiology
Propofol and alfentanil together provide rapid induction and maintenance of general anesthesia through GABA receptor potentiation and opioid receptor activation, respectively. - Sedation Etomidate combined with propofol · RenJi Hospital · Anesthesia
A combination of two intravenous anesthetic agents that work synergistically to produce rapid sedation and hypnosis through GABAergic and other central nervous system pathways. - Propofol/Lidocaine · NYU Langone Health · Anesthesiology
Propofol and lidocaine together provide rapid induction and maintenance of anesthesia with reduced pain on injection through synergistic central nervous system depression. - Propofol + Alfentanil · Region Jönköping County · Anesthesiology
Propofol and alfentanil together provide rapid induction and maintenance of general anesthesia through synergistic central nervous system depression. - ketamine and propofol · Ain Shams University · Anesthesiology
This is a combination of two intravenous anesthetic agents that work synergistically to produce rapid sedation and anesthesia through different mechanisms.
Phase 3 pipeline (1)
- Propofol + Remifentanyl · Azienda Ospedaliera San Gerardo di Monza · Anesthesiology
Propofol and remifentanil together provide rapid-onset sedation and analgesia by depressing the central nervous system through GABA potentiation and opioid receptor agonism, respectively.
Patent intelligence
- intravenous anesthetic combination patent landscape — aggregated cliff calendar, attackable patents, originator estates